Bioject Medical Technologies Inc.’s Intradermal Needle-Free Delivery System Used in World Health Organization Clinical Trial in Oman with Poliovirus Vaccine

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, today announced that Bioject’s needle-free injection delivery technology was used to successfully demonstrate that intradermal administration of fractional doses of inactivated poliovirus vaccine given to infants is safe and effective (using seroconversion as an indication of effectiveness), and is preferred by both health care administrators and parents over typical full-dose needle and syringe. The study results, published in the June 24, 2010, issue of The New England Journal of Medicine (NEJM Vol. 362 No. 25), also demonstrated a significant cost savings in use of the fractional-dose intradermal injection as compared with a full-dose vaccination course of treatment using an auto-disable needle and syringe.